PPARG and cardiovascular disorder: Additionally, the pharmacokinetic behaviors and clinical properties of TEL have reported that TEL can be a partial agonist of Peroxisome proliferator-activated receptor γ (PPARγ), and it can simultaneously block the angiotensin II receptor and activate PPARγ to effectively treat diabetes and cardiovascular disease [14].